

## Special Issue

# Cardiomyopathy and Precision Medicine

### Message from the Guest Editor

The diagnosis of the most common forms of cardiomyopathies, dilated and hypertrophic cardiomyopathies, have long been based on morphology and function by non-invasive diagnostic modalities (e.g., echocardiography). In addition, despite extensive studies on biophysical, cellular, and animal models, the current approaches to the management of patients with cardiomyopathies remain largely unchanged. Recent advances in genetics, proteomics, metabolomics, and microbiomics broadened our understanding of the molecular and cellular pathophysiology of cardiovascular diseases including cardiomyopathies, which can potentially lead to more precise risk prediction and the discovery of the optimal treatment strategies for individual patient. Also, novel approaches such as artificial intelligence and machine learning to medical big data from various sources including clinical registries, electronic health records, biomarkers, medical images, and all spectrum of 'omics' data (e.g., genomic, proteomic, and metabolomic data) have a huge potential of empowering personalized medicine for cardiomyopathy patients.

---

### Guest Editor

Dr. Yuji Nagatomo

Department of Cardiology, National Defense Medical College,  
Tokorozawa, Saitama 359, Japan

---

### Deadline for manuscript submissions

closed (31 July 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 7.2  
Indexed in PubMed



[mdpi.com/si/81747](https://mdpi.com/si/81747)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 7.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 23 days after submission; acceptance to publication is undertaken in 4.6 days (median values for papers published in this journal in the first half of 2026).